ARCH Venture Partners IX, LLC bought $25.0M of Lyell Immunopharma (LYEL)

Executed Nov 4, disclosed Nov 5, 1 day later.

Value, as filed

$25.0M

2,321,262 sh × $10.77

Executed

Nov 4

the trade date, as filed

Disclosed

Nov 5

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

not yet measured

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

The filer

AL ARCH Venture Partners IX, LLC 10% owner profile →

ARCH Venture Partners IX, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Lyell Immunopharma, Inc. (LYEL). Across 1 priced purchase filing, the average 21-session return was +0.4% from execution and -6.9% from disclosure (delay-adjusted; derived). The largest single filing was $25.0M of LYEL (2,321,262 sh × $10.77, as filed), executed Nov 4.

The name

LYEL

Lyell Immunopharma, Inc. LYEL · Healthcare · 9 filings in 24 months ticker →

Healthcare · Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for pat…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by ARCH Venture Partners IX, LLC in LYEL

LYELPURCHASE Lyell Immunopharma, Inc. $12.5M
488,090 sh × $25.61
Exec Mar 6
Filed Mar 9 · 4:36 PM ET